PolyPid Adds Kynatrix-Based PD01b for Diabetic Foot Infections to Pipeline
PYPD sits 69% above its 52-week low of $3.402 on elevated volume (1.9× avg).
Summary
PolyPid introduced PD01b, a new Kynatrix-based product candidate targeting diabetic foot infections, expanding its pipeline beyond D-PLEX100. The company said a pre-IND meeting and first-in-human study for PD01b are expected in the second half of 2027, so this is a long-dated addition with no near-term revenue. The more immediate item is the D-PLEX100 PDUFA goal date of November 28, 2026, roughly a month away, which is the binary event that matters for the stock. This follows the October 1 EMA validation of the D-PLEX100 marketing application and the mutual termination of the ADVANZ European license, leaving PolyPid to commercialize in Europe itself. The company remains thinly capitalized after a Q2 net loss and going-concern doubt, so pipeline expansion is strategic rather than funded. Watch the November 28, 2026 FDA decision on D-PLEX100.
At the time of this announcement, PYPD was trading at $5.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $117.2M. The 52-week trading range was $3.40 to $5.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.